Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients With Advanced Solid Tumors
This study is testing a new experimental drug called PM14 to see if it can help stop or slow the growth of advanced solid tumors. It is important because it explores new treatment options for patients when standard cancer therapies are no longer working.
This study is for adults over 18 who have an advanced solid tumor that has not responded well to standard treatments. You must be well enough to carry out daily activities and have a healthy heart, as certain heart conditions may prevent you from participating.
Participants will receive the experimental drug PM14 through an intravenous infusion, which means it is given directly into your bloodstream through a vein. Doctors will carefully monitor your health and watch for any side effects to learn how the body reacts to different doses of the medication.
This study was conducted at clinical centers in Boston, Houston, and Villejuif, France. The study is now officially completed.
- 1Researchers are testing if PM14 is a safe and effective way to treat advanced cancers.
- 2The study helps doctors find the right dose of this new drug for future patients.
- 3Participants must meet specific health criteria, particularly regarding heart health, to take part.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.